Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 10;6(1):e000896.
doi: 10.1136/bmjophth-2021-000896. eCollection 2021.

Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective

Seenu M Hariprasad  1 , George Joseph  2 , Patrick Gagnon-Sanschagrin  3 , Elizabeth Serra  3 , Subrata Bhattacharyya  4 , Jérôme Bédard  3 , Annie Guérin  3 , Thomas Arno Albini  5
Affiliations

Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer's perspective

Seenu M Hariprasad et al. BMJ Open Ophthalmol. .

Abstract

Objective: To describe patient characteristics and healthcare costs associated with uveitic macular oedema (UME) in US clinical practices from a commercial payer's perspective.

Methods and analysis: The IBM MarketScan Commercial Subset (1 October 2015-31 March 2020) was used to identify patients with non-infectious uveitis (NIU), with or without UME. Patients with UME at any time were further classified into subgroups of patients who received a UME diagnosis during the study period and those who received a UME diagnosis and local steroid injection (LSI) during the study period. Demographic and clinical characteristics, NIU-related treatments and healthcare costs were described for each cohort and subgroup during the most recent 12 months of continuous health plan enrolment. Healthcare costs were also described by vision status among all patients with NIU.

Results: A total of 36 322 patients with NIU were identified, of whom 3 301 (9.1%) had UME and 33 021 (90.9%) had no UME. Patients with UME more frequently received NIU-related treatment compared with those without UME (64.6% vs 45.0%), particularly LSI treatment (12.5% vs 0.7%). Mean total all-cause healthcare costs per-patient-per-year (PPPY) were higher among patients with UME ($19 851) than patients without UME ($16 188) and were especially high among those with bilateral UME ($24 162). Further, vision loss was more commonly observed in those with UME versus those without UME (5.7% vs 2.2%) and a trend of increasing healthcare costs with increasing vision loss was observed.

Conclusion: NIU is associated with substantial clinical and economic burden, particularly when UME is present.

Keywords: choroid; drugs; inflammation; macula.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SMH is a consultant or on the speakers bureau for Allergan; Bausch Health US; Novartis Pharmaceuticals Corporation; Biogen; EyePoint Pharmaceuticals; Alimera Sciences; Spark Therapeutics and Regeneron Pharmaceuticals. GJ is an employee of Bausch Health US, which funded the development and conduct of this study and manuscript. PG-S, ES, JB and AG are employees of Analysis Group, a consulting company that has provided paid consulting services to Bausch Health US. TAA is consultant for Adverum Biothechnologies; Allergan; Genentech; Novartis Pharmaceuticals Corporation; Beaver-Visitec International; EyePoint Pharmaceuticals; Bausch Health US and NGM Biopharmaceuticals.

Figures

Figure 1
Figure 1
NIU-related treatments. LSI, local steroid injection treatment; NIU, non-infectious uveitis; UME, uveitic macular oedema.
Figure 2
Figure 2
Mean annual healthcare costs by UME status. LSI, local steroid injection treatment; NIU, non-infectious uveitis; UME, uveitic macular oedema.
Figure 3
Figure 3
Mean annual total all-cause healthcare costs by uveitic macular oedema (UME)-affected eye(s). LSI, local steroid injection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Thorne JE, Suhler E, Skup M, et al. . Prevalence of noninfectious uveitis in the United States: a Claims-Based analysis. JAMA Ophthalmol 2016;134:1237–45. 10.1001/jamaophthalmol.2016.3229 - DOI - PubMed
    1. Massa H, Pipis SY, Adewoyin T, et al. . Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 2019;13:1761–77. 10.2147/OPTH.S180580 - DOI - PMC - PubMed
    1. Rosenbaum JT, Bodaghi B, Couto C, et al. . New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum 2019;49:438–45. 10.1016/j.semarthrit.2019.06.004 - DOI - PubMed
    1. Fardeau C, Champion E, Massamba N, et al. . Uveitic macular edema. Eye 2016;30:1277–92. 10.1038/eye.2016.115 - DOI - PMC - PubMed
    1. Accorinti M, Okada AA, Smith JR, et al. . Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm 2019;27:169–80. 10.1080/09273948.2019.1576910 - DOI - PubMed

LinkOut - more resources